drugset / Trial / NCT06051617
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
RandomizedParallel-groupDouble-blindTreatment
Summary
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Timeline
- Start
- 2023-09-07
- Primary completion
- 2030-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seladelpar | Small molecule | 5 mg | — |
| Subject | Seladelpar | Small molecule | 10 mg | — |